Sanofi infant vaccine gets EU approval
PARIS, April 22
PARIS, April 22 (Reuters) - French drug maker Sanofi SA said on Monday the European Commission has approved its primary and booster vaccine for infants from six weeks of age.
The vaccine protects infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type B.
The new vaccine will be commercialized by Sanofi Pasteur, the vaccines division of Sanofi, under the brand name Hexyon in Western Europe and Hexacima in Eastern Europe. (Reporting by Astrid Wendlandt; Editing by Daniel Magnowski)
- Deadly gun attack in eastern Ukraine shakes fragile Geneva accord |
- Japan expands army footprint for first time in 40 years, risks angering China
- Pfizer considers $100 billion bid for AstraZeneca: report
- Prosecutors extend Korea ferry captain's detention as death toll mounts |
- Rubin 'Hurricane' Carter, U.S. boxer famous in folk song, dies at 76